Sephience launch outpaces legacy declines
- Sephience generated $151.3 million in Q2 2026, driving more than half of product revenue.
- The older Duchenne muscular dystrophy drugs are fading, with Emflaza losing its final orphan exclusivity in June 2026.
- Vatiquinone is delayed by a required 24-month open-label study starting in late 2026.
- Cash climbed to $2.23 billion after a $550 million convertible note offering.
A launch-led turnaround
PTC has become a Sephience story. The PKU drug brought in $151.3 million of revenue in Q2 2026, including $127.6 million in the U.S. and $23.8 million internationally. This strong execution solidifies Sephience as the primary revenue driver, far outpacing the older products.
The bull case is simple. If Sephience keeps this pace, it can more than offset the decline in the old Duchenne muscular dystrophy business and move PTC closer to profit. The company also issued $550 million in convertible notes to bring cash to $2.23 billion, which gives it ample time to fund launches and research.
The bear case is concentration. PTC now leans hard on one new drug. Translarna depends on uneven government orders after losing key European access. Emflaza lost its remaining orphan exclusivity for ages 2 to 5 in June 2026, accelerating pressure from 10 generics. Vatiquinone also moved further out because the new study uses a 24-month endpoint.
Votoplam adds longer-term upside. The Huntington's disease program showed 52% slowing of disease progression against a matched natural history group at 24 months, and Novartis is running a major Phase III study. That helps the future story, but it does not fix the near-term need for Sephience execution.
Rare disease drugs, launch risk
PTC makes money mainly by selling rare disease drugs. Its key products are Sephience, Translarna, Emflaza, and Upstaza or Kebilidi. It also can earn collaboration revenue, such as upfront payments and milestones from partners.
This model can work well when a drug reaches a small patient group with few good options. Prices can be high, and the sales force can be focused. But it breaks when a drug loses exclusivity, loses market access, or fails to win approval.
PTC has a long history of losses and has used stock sales, convertible debt, partnerships, and royalty sales to fund itself. As of December 2025, it had sold 100% of its Evrysdi royalty rights to Royalty Pharma. That brought cash in, but it also removed a future royalty stream.
The next test is not whether PTC can discover rare disease drugs. It is whether Sephience can stay large enough, and profitable enough, to replace falling DMD revenue while the pipeline matures.
What PTC sells and studies
Sephience
Sephience treats phenylketonuria, or PKU, a rare inherited disorder that causes harmful buildup of phenylalanine. It is approved in the U.S., EEA, Japan, and other regions, and is now PTC's main growth driver.
Translarna
Translarna treats nonsense mutation Duchenne muscular dystrophy outside the U.S. and EEA. Sales are under pressure after the EEA authorization was not renewed, and revenue increasingly depends on lumpy one-time government orders.
Emflaza
Emflaza treats Duchenne muscular dystrophy in the U.S. Its final orphan drug exclusivity ended in June 2026, accelerating erosion against 10 generics.
Upstaza and Kebilidi
This gene therapy treats AADC deficiency, a very rare nervous system disorder. It is approved in the EEA, UK, and U.S., with Kebilidi as the U.S. brand.
Tegsedi and Waylivra
PTC licenses these medicines for commercialization in Latin America. They add breadth, but they are not the main driver of the current thesis.
Vatiquinone
Vatiquinone is being developed for Friedreich ataxia. After an FDA complete response letter, PTC plans a new open-label study with a 24-month primary endpoint starting in mid-2026.
Votoplam
Votoplam, also called PTC518, targets Huntington's disease through RNA splicing. Positive 24-month data support the partnered Novartis Phase III program.
Q2 mix shifts heavily to Sephience
PTC reports as one segment, so this mix uses Q2 2026 net product revenue. Sephience generated $151.3 million of the $238.8 million total product revenue, highlighting high concentration.
What could go wrong
Sephience launch slows
High impact · Medium oddsPTC's growth story now depends on Sephience. If U.S. start rates fall, or if international expansions realize much lower margins, revenue and profitability targets could be missed.
DMD revenue falls faster
High impact · High oddsEmflaza lost its final orphan exclusivity in June 2026 and faces 10 generics. Translarna lacks EEA authorization and relies on lumpy orders from markets like Brazil and Russia.
Vatiquinone stays delayed
Medium impact · High oddsThe FDA issued a complete response letter for vatiquinone. PTC now plans a study with a 24-month endpoint, pushing any likely resubmission into 2028 or later.
Cash burn accelerates
Medium impact · Medium oddsPTC has $2.23 billion in cash after a recent convertible note issuance. But the company has a history of losses, and it sold 100% of the Evrysdi royalty stream. Future profitability depends entirely on product sales.
Votoplam Phase III fails
Medium impact · Medium oddsVotoplam has encouraging data, but it still needs Phase III proof in Huntington's disease. A failure would remove a major long-term option.
In one breath
What is PTC Therapeutics best known for now?
PTC is now best known for Sephience, its PKU drug. In Q2 2026, Sephience brought in $151.3 million and generated over half of total product revenue.
Why are Translarna and Emflaza a problem?
Both are older Duchenne muscular dystrophy products with falling durability. Translarna lost EEA authorization, while Emflaza faces 10 generics after its final orphan drug exclusivity expired in June 2026.
Does PTC still get Evrysdi royalties?
No. As of December 2025, PTC sold 100% of its Evrysdi royalty rights to Royalty Pharma, trading future royalties for upfront cash.
What is the next big pipeline event?
The most important near-term pipeline step is starting the new vatiquinone study in late 2026. The main long-term option is votoplam in Huntington's disease, where Novartis is running a Phase III program.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 30, 2026
- Score data
- September 6, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near PTC Therapeutics, Inc. in Finn's Biotechnology industry ranking.
